

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*
(於中華人民共和國註冊成立的股份有限公司)
(股份代號：1513)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following announcement titled “Announcement on Unusual Movements in Trading of Shares of Livzon Pharmaceutical Group Inc.*” published by Livzon Pharmaceutical Group Inc.* (the “**Company**”) on the website of the Shenzhen Stock Exchange is set out below for reference only.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Company Secretary
Liu Ning

Zhuhai, China
29 September 2026

As at the date of this announcement, the executive directors of the Company are Mr. Liu Daping (Chairman and President) and Mr. Tang Yanggang (Vice Chairman); the non-executive directors of the Company are Mr. Lin Nanqi and Mr. Qiu Qingfeng; the employee representative director of the Company is Ms. Ran Yongmei; and the independent non-executive directors of the Company are Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li.

** For identification purpose only*

LIVZON PHARMACEUTICAL GROUP INC.*

ANNOUNCEMENT ON UNUSUAL MOVEMENTS IN TRADING OF SHARES

The Company and all members of the Board of Directors warrant that the information disclosed is true, accurate and complete and contains no false records, misleading statements or material omissions.
--

I. OVERVIEW OF UNUSUAL MOVEMENTS IN TRADING OF SHARES

The cumulative deviation of the closing price movements of the A Shares of the Company (stock abbreviation: Livzon Group; stock code: 000513) reached 20.82% over three consecutive trading days on 24, 28 and 29 September 2026. Pursuant to the relevant provisions of the Shenzhen Stock Exchange, this constitutes unusual movements in trading of shares.

II. INFORMATION OF CONCERN AND VERIFICATION BY THE COMPANY

In response to the unusual movements in trading of the Company's shares, the Company verified the relevant matters. The circumstances that may affect the unusual movements in trading of the Company's shares are set out as follows:

1. No correction or supplement to the information previously disclosed by the Company is required;
2. Regarding recent media reports, the Company has not identified any recent reports in the public media containing undisclosed material information that may have had or has had a significant impact on the trading price of the Company's shares.
3. The Company's recent operations are normal, and there have been no material changes in its internal or external operating environment.
4. Neither the Company, its controlling shareholder nor its actual controller has any material matter concerning the Company that should be disclosed but has not been disclosed, nor is there any material matter at the planning stage.
5. Neither the controlling shareholder nor the actual controller of the Company traded in the Company's shares during the period of unusual movements in trading of the Company's shares.

III. STATEMENT ON WHETHER THERE IS ANY DISCLOSEABLE BUT UNDISCLOSED INFORMATION

The Board of the Company confirms that the Company currently has no matter that should be disclosed but has not been disclosed under the Rules Governing the Listing of Shares on the Shenzhen Stock Exchange and other relevant provisions, nor any planning, negotiation, intention or agreement relating to such matter. The Board is also not aware of any information relating to the Company that should be disclosed but has not been disclosed under the Rules Governing the Listing of Shares on the Shenzhen Stock Exchange and other relevant provisions and that may have a significant impact on the trading prices of the Company's shares and derivatives. No correction or supplement to the information previously disclosed by the Company is required.

IV. NECESSARY RISK WARNINGS

1. Upon self-examination, the Company has not violated the requirements for fair disclosure of information.

2. The Board of the Company solemnly reminds investors that China Securities Journal, Securities Times, Shanghai Securities News and CNINFO (website: <http://www.cninfo.com.cn>) are the media designated by the Company for information disclosure. All information of the Company shall be subject to the information published in the designated media.

The Company will strictly comply with the provisions and requirements of the relevant laws and regulations, conscientiously fulfil its information disclosure obligations and make information disclosure in a timely manner. Investors are advised to invest rationally and pay attention to risks.

This announcement is hereby made.

The Board of Directors of Livzon Pharmaceutical Group Inc.*

30 September 2026